ClinicalTrials.gg
RecruitingNCT05094570Updated Apr 1, 2025

Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP

A Phase 4 interventional study of Dupilumab Prefilled Syringe in Nasal Polyps and Staphylococcus Aureus, sponsored by University of Virginia. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-01.

Sponsored by University of Virginia · Phase 4, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing dupilumab in Nasal Polyps — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Nasal Polyps.

Planned enrollment
12th of 16
20 · median 45
Started
2022
the only one that year
Phase 4
10 of 16
4 open now
Registered
8th of 16
by date
Lead sponsor
1 of 16
University of Virginia

Among the 16 studies testing dupilumab in Nasal Polyps, this one is the 12th largest by planned enrollment, is the only one that started in 2022, is one of 10 in phase 4, and was the 8th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

4 of the 16 studies testing dupilumab in Nasal Polyps are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing dupilumab in Nasal Polyps, or all of them as a file.
02

Study summary

Hypothesis: The investigators hypothesize that in patients with CRSwNP who demonstrate sinus colonization with staphylococcus aureus, the administration of dupilumab will be associated with decreased staph colonization and an increase in microbial diversity.

Primary Objective will be to demonstrate that dupilumab reduces staphylococcus aureus (phyla firmicutes) abundance while increasing microbial diversity in patients with CRSwNPs who are culture positive for staph aureus at enrollment.

Secondary Objectives will be to correlate reduction in Staph aureus abundance and improved bacterial diversity with increased expression of anti-microbial proteins (ß-defensins1-4) and cathelicidin LL-37. In addition, the investigators will correlate improvements in microbial diversity/decreased staph abundance with clinical improvements as assessed via questionnaires and objective/subjective smell function and also as improvements in cellular/immune T2 inflammation as assessed by reduced expression of T2 cytokines/chemokines and eosinophil/eosinophil-derived proteins.

Read the detailed description

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is an important clinical problem and is associated with profound unmet medical needs given the absence - until recently - of adequate medical therapies. It has an estimated prevalence of 2-4% in the USA and Europe but also has disproportionate burden on quality of life and economic burden.

CRSwNPs is predominantly (in 62-85% of patients) a type 2 (T2) disease, as demonstrated by an IL-4high, IL-5high, IL-13high cytokine signature and prominent infiltration with eosinophils, basophils, and newly recruited mast cells. Another characteristic feature of CRSwNPs is the colonization of the sinonasal space with Staphylococcus aureus (Staph). Staph comprises \<10% of the bacterial biomass of the healthy nose but infections with this pathogen is observed in the majority of CRSwNP patients and especially in those with asthma comorbidity or AERD.

Evidence exists for an upregulatory vicious circle involving type 2 inflammation promoting an immune deficient state with reduced innate immune responsiveness to staph, leading to colonization/infection with staph and then with the staph producing exotoxins and other pathogen-associated molecular patterns (PAMPs) that promote and exacerbate the T2high state. A central endogenous immune defense to protect against colonization and infection with staph consists of innate immune-derived anti-microbial proteins (AMPs). There are two major families of AMPs, the defensins and the cathelicidins that together comprise >2000 proteins. These cationic proteins provide immune defenses against a range of pathogens. Downregulation of the ß-defensins (BD)-2 and BD-3 and cathelicidin LL-37 is particularly relevant to atopic dermatitis (AD) and underlies the particular susceptibility of AD skin to colonization and infection with staph. Thus, in AD staph can comprise up to 90% of the bacterial species present on the skin. These AMPs are predominantly expressed in epithelial cells including of the skin but are also expressed by airway epithelial cells (AECs). Sinonasal AECs produce all the ß-defensins (BD1-4) and BD1-3 expression is reduced in allergic inflammatory diseases of the airway. In addition to AMPs shared with the dermis, another important AMP, S100A7 (psoriasin) is also uniquely reduced in CRS.

This diminished expression of ß-defensins and cathelicidin in AD has been ascribed to overproduction of IL-4/IL-13. Inhibition of AMP expression in upper airway allergic disease has also been ascribed to these cytokines. In addition to inhibiting its production, IL-4/IL-13 also block the mobilization of BD-3 to the surface of staph. T2 cytokines further promote staph infection in AD by enhancing binding of these pathogens to atopic skin. Finally, IL-4/IL-13 may further enhance susceptibility to infection through their adverse impact on tight junction barrier function, thereby promoting microinvasive disease and access of PAMPs to submucosal targets.

The final component of the pro-inflammatory vicious circle is the capacity of Staph-derived enterotoxins to feedback to enhance production of T2-associated cytokines, thereby further exacerbating eosinophilic inflammation and the reduced innate immune defense against pathogens. This enhancement of the T2 signature has traditionally been ascribed to the production of superantigens (and antigens) by staph that engage Th2 effector cells residing in the sinuses via their T cell receptor and stimulates their further activation and cytokine secretion. However, staph-derived PAMPs including lipoteichoic acid and staph enterotoxin B (SEB) can also induce secretion of T2-promoting cytokines such as IL-33 and TSLP by engagement of toll-like receptor (TLR)2 and other pathogen recognition receptors (PRRs) on AECs.

In summary CRSwNPs frequently comprises a state in which staph-derived PAMPs exacerbate an already established T2high inflammatory condition, T2-derived cytokines but in particular IL-4 and IL-13 interact with AECs to reduce AMP production, and reduced expression of AMPs promotes the colonization and further infection with staph.

This pathogenic mechanism is now unambiguously established in atopic dermatitis. This was demonstrated via the ability of blockade of IL-4/IL-13 via administration of anti-IL-4R to decrease Staphylococcus aureus colonization and increase microbial diversity in atopic dermatitis - an effect that strongly correlated with clinical benefit. The investigators propose that a similar molecular mechanism for dupilumab will be observed in CRSwNPs.

03

Conditions studied

  • Nasal Polyps
  • Staphylococcus Aureus

Keywords

  • Nasal polyps
  • Staph aureus
  • Interleukin-4/-13
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: • Adults, ages 18-65

  • History of CRSwNP including subjects with AERD
  • Sinonasal culture demonstrating staph aureus at visit 1
  • History of FESS with patent sinus ostia sufficient to obtain culture and tissue samples from the middle meatus
  • Asthma, if present, should be well controlled
  • Atopic dermatitis, if present, should be well controlled
  • Use of nasal saline irrigation and stable dosing (>1 month) of topical is permitted
  • Intent of the physicians caring to start dupilumab therapy as part of subject's standard of care
  • Subject meets FDA approved criteria for the use of dupilumab for nasal polyps

Exclusion Criteria:

  • Concurrent serious medical problem
  • Uncontrolled asthma (ACT \<20 at screening visit)
  • Recent (within 60 days) use of oral corticosteroids
  • Recent (within 60 days) urgent care, ED visit, or hospitalization for asthma
  • Current smoker or has smoked >10 pack-years
  • Biologic therapy including asthma biologic therapy in last 3 months
  • Recent (within 1 month) change in CRS medical treatment (topical steroids, surfactants, irrigation protocol, etc. including changes in delivery volume or delivery methodology)
  • Recent (within 6 weeks) upper respiratory infection
  • Antibiotics within 6 weeks
  • Pregnant or breast-feeding women
  • Any to the use of dupilumab including on previous administration
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Dupilumab treatment

    Treatment with dupilumab to demonstrate decreased staph prevalence and improve microbial diversity

    Drug: Dupilumab Prefilled Syringe

Interventions

06

What researchers measure

Primary outcomes

  1. To demonstrate that dupilumab reduces staphylococcus aureus

    To demonstrate that dupilumab reduces staphylococcus aureus (phyla firmicutes) abundance. The abundance of Staph aureus will be determined using qPCR of the femA gene and compared at baseline and after 16 weeks of dupilumab treatment. Statistical differences in the quantity of staph aureus (as ascertained by qPCR) will be determined utilizing data obtained from all subjects comparing data obtained at the end of the study in comparison to the beginning of the study.

    Time frame: 16 weeks

Secondary outcomes

  1. To correlate reduction in Staph aureus with improvements in clinical status

    To correlate reduction in Staph aureus abundance and improved bacterial diversity with increased expression of anti-microbial proteins (ß-defensins1-4) and cathelicidin LL-37. These parameters will be determined using quantitative PCR. In addition, we will correlate improvements in microbial diversity/decreased staph abundance with clinical improvements as assessed via questionnaires and objective/subjective smell function and also as improvements in cellular/immune T2 inflammation as assessed by reduced expression of T2 cytokines/chemokines and eosinophil/eosinophil-derived proteins. These will be determined using proximity extension assays (for cytokines/chemokines) and enzyme immunoassays for eosinophil products. Statistical significance of data obtained at end of study will be determined in comparison to baseline samples.

    Time frame: 16 weeks

  2. To demonstrate that dupilumab increases microbial diversity

    To demonstrate that increases microbial diversity in CRSwNPs who are culture positive for staph aureus at enrollment. Microbial ß-diversity will be quantified via the Shannon Index and compared between baseline and 16-week samples. Microbial diversity (as ascertained by Shannon diversity) will be determined utilizing data obtained from all subjects comparing data obtained at the end of the study in comparison to the beginning of the study.

    Time frame: 16 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2022 (actual). Primary completion is estimated for Jun 2026, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2021
First posted
Oct 26, 2021
StartActual
Sep 1, 2022
Primary completionEst.
Jun 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05094570
Responsible party
Larry Borish, MD (Professor of Medicine and Microbiology, University of Virginia) — Principal investigator
First posted
Oct 26, 2021
Start date
Sep 1, 2022
Primary completion
Jun 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 1, 2025

Study contacts

Kristin W Wavell Shifflett, BS
Contact
kww7d@virginia.edu
4349246874
Deborah Murphy, BSN
Contact
ddm9q@virginia.edu
4349823510
Larry C Borish, MD
principal investigator · University of Virginia

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion